Vonafexor(PLX007,EYP-001)

Modify Date: 2024-01-13 17:15:19

Use of Vonafexor(PLX007,EYP-001)

Vonafexor (EYP001) is a selective FXR agonist with anti-HBV effects[1][2].

Name	Vonafexor

Description	Vonafexor (EYP001) is a selective FXR agonist with anti-HBV effects[1][2].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Metabolic Enzyme/Protease >> FXR Signaling Pathways >> Anti-infection >> HBV
References	[1]. Joly S, et al. The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells. J Hepatol 66(1):S690. [2]. Fiorucci S,et al. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH) [published online ahead of print, 2020 Jun 19]. Expert Opin Investig Drugs. 2020;1-10.

Description

Vonafexor (EYP001) is a selective FXR agonist with anti-HBV effects[1][2].

Related Catalog

Research Areas >> Infection

Signaling Pathways >> Metabolic Enzyme/Protease >> FXR

Signaling Pathways >> Anti-infection >> HBV

References